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Abstract 
Purpose Treatment options for recurrent or metastatic differentiated thyroid cancer (DTC) 
refractory to radioactive iodine (RAI) are inadequate. Multitargeted kinase inhibitors have recently 
shown promising results in phase 2-3 studies. This retrospective study aimed to document our 
clinical experience on the effects of sorafenib in the setting of daily clinical practice. 
Methods Retrospective study evaluating the efficacy and safety of sorafenib in a cohort of patients 
consecutively treated with sorafenib at a single centre. Twenty patients with advanced RAI-
refractory thyroid carcinoma were enrolled (March 2011-March 2014). Patients generally started 
with sorafenib 400 mg twice daily, tapering the dose in case of side effects. Radiological response 
and toxicity were measured during follow-up, together with safety parameters. CT scans were 
performed by a single experienced radiologist every 3-4 months. 
Results Five patients stopped sorafenib within 90 days for severe toxicities. Median progression 
free survival was 248 days. Five patients had a partial response (PR), achieved in all cases within 3 
months, whereas 5 had stable disease (SD) at twelve months. Durable response rate (PR plus SD) 
for at least 6 months was 50%, among those who received sorafenib for at least 3 months. 
Commonest adverse events included skin toxicity, gastrointestinal and constitutional symptoms. 
Conclusions In our cohort of patients with advanced RAI-refractory thyroid carcinoma, sorafenib 
confirmed antitumor activity leading to SD or PR in the majority of cases, at the expense of 
clinically relevant side effects. More effective and tolerable agents are still needed in the 
treatment of RAI-refractory DTC. 
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Introduction 
Thyroid carcinoma is the most frequent endocrine cancer, despite accounting for approximately 
2% of all tumours [1]. According to the American Cancer Society, it is the sixth most frequently 
diagnosed cancer in female subjects and the eighth in men [2]. Its annual incidence has been 
steadily increasing, doubling in the last 30 years. In 2013, over 60,000 new cases of thyroid cancers 
were expected to develop in the United States [3, 4]. Although this cancer is generally regarded an 
indolent disease, the total annual mortality rate for thyroid cancer is about 3% in the United 
States. These deaths have been reported to be more than those for Hodgkin's lymphoma, 
osteosarcoma, and testicular cancer [5]. 
Differentiated thyroid carcinomas (DTCs) consist of papillary thyroid carcinoma (PTC) and follicular 
thyroid carcinoma (FTC), with their different histological subtypes. They constitute the vast 
majority of thyroid cancers: PTC accounts for over 85% of all cases while FTC accounts for 5-10%. 
Poorly differentiated thyroid carcinoma (PDTC) is rarer and it has recently been acknowledged as 
an autonomous entity, characterized by clinical and histological aspects that place them in an 
intermediate position between DTC and anaplastic thyroid carcinoma [6-8]. 
Generally, thyroid carcinomas are slow growing and highly curable by a combination of surgery, 
radioactive iodine (RAI) ablation, and TSH-suppressive doses of L-thyroxine. However, 10-20% of 
patients show progressive disease, and half of them become refractory to RAI; this event is 
associated with a high relapse rate and shorter survival [9-12]. Treatment options for thyroid 
cancers no longer responsive to standard therapy and that are characterized by progressive de-
differentiation are currently limited. Traditional chemotherapeutic agents generally provide 
disappointing results, along with considerable side effects [3, 13]. Even external beam radiation 
therapy (EBRT) does not show effectiveness in advanced thyroid carcinomas, being used only for 
palliation [3]. In order to develop new therapeutic strategies, in recent years pre-clinical and 
  4 
clinical studies have been conducted in particular on tyrosine kinase inhibitors (TKIs)[14, 15]. 
Among these, sorafenib, an oral multikinase inhibitor with antiproliferative and antiangiogenic 
effects acting at the level of the signal transduction pathways of RAS and BRAF/MEK/ERK, of the 
RET/PTC receptors, of VEGF receptors 1-3, and of PDGF receptor β, showed encouraging results 
[16-18]. 
Sorafenib was originally approved for the treatment of advanced kidney cancer and of 
unresectable hepatocellular carcinoma [19]. Preliminary trials and phase 2 studies showed 
clinically relevant anti-tumour activity also in patients with metastatic, iodine-refractory thyroid 
cancer, with a partial response rate ranging from 15 to 33% and a stable disease rate of 41-82% 
[18, 20-26], together with an overall acceptable safety profile. The recently published DECISION 
trial was the first phase 3 randomized study in RAI-refractory DTC showing significantly improved 
(by 5 months) median progression-free survival with sorafenib versus placebo (10.8 vs 5.8 months, 
respectively)[27]. This data led the US Food and Drug Administration to approve sorafenib for the 
treatment of well-differentiated RAI-resistant metastatic thyroid cancer, in November 2013. 
Starting from 2011, we began treating patients with advanced thyroid cancer no longer responsive 
to conventional therapy with sorafenib, as an off-label drug. The purpose of this retrospective 
study is to document our Centre experience (in terms of efficacy and safety) in a cohort of patients 
consecutively treated with sorafenib, in the setting of a daily clinical practice. 
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Patients and methods 
Patients 
In March 2011, the Ethics Committee of our Institution approved the use of sorafenib for the 
treatment of patients with advanced iodine-refractory DTC/PDTC, after the publication of phase 2 
studies showing promising results in the induction of stable disease and occasional partial 
response in this setting. Advanced DTC was defined as progressive and/or metastatic DTC with no 
further indication for RAI therapy because of: 1) a lack of RAI uptake (partial or complete, assessed 
by I-131 whole-body scan); 2) having received cumulative RAI activity higher than 22.2 GBq (600 
mCi); 3) disease progression during conventional therapy. Patients provided written informed 
consent both for treatment with sorafenib and for entering data in our database. The local Ethical 
Committee of the University Hospital “Città della Salute e della Scienza” of Turin approved our 
retrospective analysis. 
 
Patients were enrolled if they met the following inclusion criteria: 
 age 18 years or older (females were excluded if pregnant or lactating); 
 locally advanced or metastatic RAI-refractory DTC or PDTC (at outset, according to the 
Turin proposal)[8] that had progressed within the past 12 months prior to signing informed 
consent, according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; 
 at least one measurable lesion by computed tomography (CT) or magnetic resonance 
imaging (MRI) according to RECIST at enrolment; 
 Eastern Cooperative Oncology Group (ECOG) performance status of 0–2; 
 adequate bone marrow, blood coagulation, liver, and renal function; 
• adequately controlled blood pressure (BP) with or without antihypertensive medications, 
defined as BP < 150/90 mmHg; 
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Patients were excluded if they had significant cardiovascular impairment: history of congestive 
heart failure greater than New York Heart Association (NYHA) class II, unstable angina, myocardial 
infarction or stroke within 6 months, cardiac arrhythmia requiring medical treatment, or 
prolongation of QTc. Patients who had previously been treated with traditional chemotherapy or 
with EBRT were not excluded. 
 
Therapy with sorafenib  
Eligible patients started treatment with sorafenib 800 mg/day (2x200 mg tablets twice daily) or 
with 600 mg/day in case of relevant comorbidities, maintaining TSH-suppressive doses of L-
thyroxine. The follow-up was generally carried out on a monthly basis to coincide with the renewal 
of the prescription of sorafenib, or more frequently according to the clinical situation. 
Furthermore, each patient had the opportunity to contact us via phone or email at any time of the 
study. The drug dose was sequentially reduced or interrupted in case of important side effects, 
according to previous recommendations [28]. Treatment continued until disease progression or 
unacceptable toxicity. 
 
Laboratory parameters and imaging restaging 
Serum TSH, free-thyroxine (T4), thyroglobulin (Tg), and Tg antibody levels were measured at all 
visits, together with safety parameters. These included blood cell count, serum levels of sodium, 
potassium, lipids, creatin kinase (CK), N-terminal pro-brain natriuretic peptide (NT-proBNP), blood 
coagulation, liver, and renal function. 
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Restaging of disease with CT scan was performed at month 3 from the start of treatment in 
patients who had taken the drug for at least 30 days. Patients in long-term therapy were also 
restaged by CT scan every 3-4 months. All CT images were evaluated by a single radiologist. 
 
Outcomes  
The study outcomes were efficacy and safety of sorafenib in patients with advanced iodine-
refractory DTC/PDTC. In order to evaluate efficacy, we considered as endpoints the overall and 
progression free survival, and the objective response rate (complete or partial response). 
The radiologic response to therapy with sorafenib was classified according to the RECIST 1.1 
criteria as complete remission of disease (CR), partial response (PR), stable disease (SD), or 
progressive disease (PD).  
Safety was assessed according to National Cancer Institute Common Terminology Criteria for 
Adverse Events (CTCAE) version 3.0. In order to evaluate safety, we considered occurrence of any 
adverse event and of severe adverse event (grade 3-4), and time to treatment discontinuation. 
 
Statistical analysis 
The distribution of patient characteristics was summarized using percentiles for continuous 
variables, and percentages and frequencies for categorical variables.  
Overall survival (OS) was defined as the elapsed time between the date of the first sorafenib 
treatment and either the date of death or the last follow-up (if death was not observed during the 
follow-up period). Progression free survival (PFS) was defined as the elapsed time between the 
first sorafenib treatment and disease progression (or death), or the last follow-up (if progression 
was not observed during the follow-up). Patients without any CT evaluation were considered as 
censored at 90 days after the first sorafenib dose, in PFS analysis. OS and PFS were estimated 
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using the Kaplan-Meier estimator. 
Time to treatment discontinuation was defined as the elapsed time between the date of the first 
sorafenib treatment and the date of sorafenib discontinuation. The cumulative incidence of 
treatment discontinuation was estimated using Kaplan-Mayer estimator. 
Statistical analyses were performed using Stata v.11.2 (StataCorp, College Station, TX, USA). 
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Results 
Patients 
From March 2011 to March 2014, twenty eligible patients were consecutively enrolled and started 
on treatment with sorafenib. Detailed demographic and clinical characteristics are reported in 
Table 1. Most of patients were female and the median age was 56.5 years (range 37-76). 
Seven out of the 20 enrolled patients had a histological diagnosis of PDTC, 9 of FTC/Hürthle cell 
carcinoma, and 4 of PTC. Time from diagnosis exceeded 5 years in 65% of patients, and distant 
metastases were present in 17 of them (70% to the lung). Tg antibodies were positive in 25% of 
the patients. All of the patients had undergone total thyroidectomy followed by remnant ablation 
with I-131 and by therapy with TSH-suppressive doses of L-thyroxine. Thirteen patients had been 
re-operated at least once (65%) for locoregional recurrences or distant disease. Three patients had 
been previously treated with chemotherapy, 7 with EBRT. Before starting sorafenib, patients had 
an ECOG score of 0 (40%), 1 (55%), and 2 (5%). Patients generally started treatment with sorafenib 
400 mg twice daily, tapering the dose in case of side effects. The median cumulative dose was 
94,800 mg (interquartile range 21,400-181,200 mg). Mean daily dose was 601,73 mg. 
Efficacy 
During follow-up, 6 deaths were recorded (5 within 12 months). Radiologic responses to sorafenib 
are shown in detail in the flow chart (Figure 1). OS at 6 and 12 months was 89.06% (95% CI 62.66; 
97.17) and 65.77% (95% CI 35.15; 84.54), respectively (Figure 2). The median survival time was 
28.38 months. Five patients discontinued sorafenib due to severe toxicity (grade 3-4) before the 
first CT scan, four of which within the first month. PFS at 6 and 12 months was 81.43% (95% CI 
52.26; 93.70) and 48.86% (95% CI 20.97; 72.01), respectively (Figure 3). The median PFS time was 
8.25 months. Durable response rate (PR plus SD) for at least 6 months was 50%, among those who 
received sorafenib for at least 3 months. 
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Although median Tg levels showed a trend toward changing accordingly to the radiological 
response (reduction, stabilization, or progression), no significant association was observed after 
exclusion of patients with Tg antibodies positivity (data not shown). 
 
Tolerability 
Most common adverse events included constitutional symptoms (fatigue, weight loss, and 
anorexia), skin toxicity (hand-foot syndrome, rash/desquamation, and alopecia), gastrointestinal 
symptoms (diarrhoea, oral mucositis), and hypertension (Table 2). These side effects were mainly 
grades 1-2 toxicity according to CTCAE. Serious adverse events included severe gastrointestinal 
toxicity (2 cases), myocardial infarction, intra-tracheal bleeding, and anaphylactic reaction (1 case 
each). Neither bone marrow toxicity nor secondary malignancies occurred in our cohort, during 
the observation period. All deaths (6/20) were attributable to underlying disease progression. 
None of the QTc prolongations observed (4/20) exceeded the upper normal limit (450 ms). NT-
proBNP, CK, and liver transaminases increased in 55%, 10%, and 35% of patients, respectively. 
Dose adjustments of L-thyroxine due to change in TSH levels (mostly increased) were needed for 
5/20 patients.  
The median duration of treatment with sorafenib was 5.75 months (CI 95% 0.99-8.02). All patients 
who started with the maximal sorafenib dose (400 mg twice daily) required either dose reduction 
and/or transient drug interruption to control adverse events. At the end of our observation, three 
patients were still on therapy with sorafenib without discontinuation (Figure 4). 
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Discussion 
Major existing guidelines suggest novel therapies with orally available anti-angiogenic TKIs for 
patients with significantly progressive, macroscopic RAI-refractory DTC, preferentially in the 
setting of experimental trials [3, 30]. New targeted therapies are thus regarded with increasing 
interest by both endocrinologists and oncologists [29, 31]. After the publication of the DECISION 
trial, sorafenib –the first drug approved for this indication- represents the first-line systemic 
approach in this setting [26, 27]. However, treatment with sorafenib is, at best, effective in 
stabilizing patients with progressive disease, with a PR rate ranging from 12 to 22% [32]. 
Our data add to the growing evidence that sorafenib can slow down tumour progression in 
patients with advanced thyroid carcinomas, at least temporarily. The results of our study are 
broadly consistent with previous ones [18, 20, 21, 26, 33]. In particular, the disease control rate 
(PR plus SD for ≥6 months) of our cohort was quite similar to the rate of the DECISION trial (50.0% 
vs 54.1%, respectively)[27]. In our study, however, progression free survival was lower than 
generally reported, with a median time of 8.25 months vs. 10-19 months [18, 20-24, 27, 34], but 
similar to other retrospective studies [25]. In our study, all of the patients treated with sorafenib 
had advanced, progressive, and aggressive thyroid cancer with high disease burden that was 
refractory to RAI. Furthermore, the cohort included some patients with PDTC. Therefore, it is 
possible that the tumour burden of our patients was higher than that of other studies. As an 
alternative hypothesis, it must be considered that the mean daily dose in our study was slightly 
lower than previous phase 2-3 clinical trials [24, 27]. 
Similarly to previous studies, also in our cohort median Tg levels changed accordingly to 
radiological response, even if no significant association was observed (likely due to the small 
number of patients). At present, if serum Tg determination can be used on an individual basis to 
monitor treatment with anti-angiogenic agents remains to be established [18, 24, 27]. During 
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tumour progression, cellular dedifferentiation occurs in up to 5% of cases, leading to poorly 
differentiated pathological features. These characteristics may include the loss of the ability to 
produce Tg [31]. 
Adverse events were generally consistent with the known safety profile of sorafenib [26, 27]. A 
substantial percentage of our patients discontinued treatment because of side-effects within 3 
months. In particular, constitutional symptoms and skin toxicity were extremely common. In 
addition, hand–foot syndrome and diarrhoea significantly affected the quality of life of those who 
remained on sorafenib. Skin reactions are sometimes difficult to control and can strongly limit 
daily routine activities. The importance of monitoring and of taking care of the skin should always 
be emphasized, when starting sorafenib treatment, also taking into account the possibility of 
development of skin squamous cell carcinomas [27]. Dose adjustments of L-thyroxine due to 
change in TSH levels were rather common in our cohort. Indeed, TSH levels should be monitored 
frequently during treatment with sorafenib, adjusting L-thyroxine dose accordingly [28]. 
Conversely, in our experience, QTc prolongation seldom represents an adverse effect of sorafenib 
treatment. Moreover, deaths were always related to underlying disease, in our cohort. 
In our cohort, most patients required either dose reduction and/or (temporary or definitive) drug 
interruption of sorafenib for adverse events, especially those who started with the maximal 
sorafenib dose. This scenario is well known in everyday clinical practice and confirmed by the 
existing meta-analysis [26, 28], but it has been the subject of few reports in the literature. 
According to previous reports, sorafenib may be better tolerated in patients with renal cell 
carcinoma than in advanced hepatocellular or thyroid carcinoma, but the reasons for this 
difference are still unclear [35]. This excess of toxicity is somewhat unexpected, because patients 
with thyroid cancer usually have a better renal function. Recently, it has been suggested that it 
could be linked to a high prevalence of sarcopenia in this population, secondary to long-term 
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thyroxine suppressive therapy leading to muscle loss [36]. 
It has to be highlighted that often patients place unrealistic expectations on the effectiveness of 
targeted therapies, and erroneously believe that these treatments are not burdened with 
significant side effects, unlike traditional chemotherapy. Actually, treatment with sorafenib 
present difficulties in daily clinical practice. Thus, a detailed discussion and obtaining written 
informed consent from the patient before initiation of TKI therapy are fundamental aspects [28]. 
Our observational study has the advantage of describing sorafenib effects in patients belonging to 
our daily clinical practice, instead of those recruited by strictly defined enrollment criteria in the 
setting of a  sponsored (or not) clinical trial. Yet, all CT images were evaluated by a single 
radiologist with longstanding experience in radiological assessment of oncological diseases. 
This study also contains several limitations, such as its retrospective design and the relatively small 
sample size, which makes impossible to draw any subgroup analysis according to patient 
characteristics or tumour histology, which was quite heterogeneous and included a third of 
patients with PDTC.  
Besides, information regarding patient quality of life during treatment with sorafenib were not 
systematically collected (e.g. with questionnaires to be completed at baseline and at regular 
intervals thereafter). 
Another limitation is that we did not perform any mutational analyses on tumour tissues. BRAF 
and RAS mutations have been associated with poor outcomes in patients with DTC [37, 38], even if 
their potential prognostic or predictive value in patients with advanced, RAI-refractory thyroid 
cancer has not been extensively evaluated. However, in the DECISION trial, sorafenib improved 
progression-free survival irrespective of BRAF or RAS mutation status, thus suggesting that these 
mutations are neither independently prognostic nor predictive of sorafenib efficacy [27]. 
Our retrospective study, showing the experience of a single centre, did not include a control 
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group, so it is not possible to argue if the outcomes observed with sorafenib were really effective 
and clinically relevant. Furthermore, some heterogeneity in drug dose was present among 
patients. Certainly, our patients showed progression of the disease during conventional therapy 
within the past 12 months, and it is likely that they would have further progressed if left 
untreated. Anyhow, target lesions shrank in over 35% of the patients who were given sorafenib 
and were restaged by CT scan at least once. 
Similarly to previous studies, the radiologic response to sorafenib was classified according to the 
RECIST criteria, even if they do not properly evaluate all the real benefits of targeted therapies in 
solid tumours [32]. However, in the absence of alternative validated criteria, RECIST is the 
mainstay of response evaluation for antitumor agents, at the moment. 
In conclusion, also in the setting of everyday clinical practice, sorafenib confirmed antitumor 
activity leading to durable response in the majority of a cohort of patients with significantly 
progressive, advanced RAI-refractory DTC/PDTC. However, our findings showing a median PFS of 
about 8 months and a high incidence of serious adverse events, together with a high rate of dose 
reductions, add to the growing evidence that more effective agents with less toxicity and possibly 
costs are still needed in the treatment of RAI-refractory DTC [26, 32]. Furthermore, responses with 
sorafenib are often not durable, and salvage target therapies after sorafenib failure have not been 
extensively evaluated yet [39]. Sunitinib may represent a feasible option in this setting, even if few 
studies have been performed so far [40]. Promising results with another TKI, lenvatinib, in the 
setting of a phase-III trial, have been reported at the recent 2014 ASCO meeting [41]. According to 
preliminary findings, lenvatinib seems more effective than sorafenib in both improving PFS and 
obtaining an objective tumour response. Moreover, the role of TKIs in this setting may be 
revolutionised by the recent findings according to which selumetinib may restore iodine uptake 
and clinical response to RAI [29]. These and other recent findings have been extensively discussed 
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by Marotta et al. in a recent review [42]. 
Physicians well-versed in the management of advanced thyroid cancers should carefully evaluate, 
on an individual basis, if starting or not systemic therapy with TKIs, as the risks of therapy can 
often outweigh potential benefits. Indeed, watchful waiting may still be appropriate for many 
cases with stable or slowly progressive asymptomatic disease, especially with patients of advanced 
age, with severe comorbidities, or scarcely motivated to tolerate unpleasant side effects. 
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Figure legends 
Figure 1 Flow chart 
Figure 2 Overall survival (OS) from the date of the first sorafenib dose (N=20). 
Figure 3 Progression free survival (PFS) from the date of the first sorafenib dose (N=20). 
Figure 4 Cumulative incidence of treatment discontinuation 
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Table 1 Main baseline demographic and clinical features of patients treated with sorafenib 
Table 2 Adverse events 
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Tab. 1 Main baseline demographic and clinical features of patients treated with sorafenib 
 All (N=20) 
 N % 
Gender   
Female 13 65.00 
Male 7 35.00 
Age (years)   
<50 4 20.00 
50-59 7 35.00 
60-69 4 20.00 
>=70 5 25.00 
Age at diagnosis (years) – median 
[range] 56.5 [37-76] 
Time from diagnosis (years) 
  
<1 3 15.00 
1-5 4 20.00 
5-10 6 30.00 
 ≥10 7 35.00 
ECOG performance status   
0 8 40.00 
1 11 55.00 
2 1 5.00 
Number of surgeries after 
thyroidectomy   
0 7 35.00 
1 6 30.00 
2 4 20.00 
3 1 5.00 
4 2 10.00 
Total cumulative radioiodine activity 
(mCi)   
  23 
 All (N=20) 
 N % 
≤100 4 20.00 
101-600 8 40.00 
601-1000 5 25.00 
≥1001 3 15.00 
Chemotherapy   
No 17 85.00 
Yes 3 15.00 
External beam radiotherapy   
No 13 65.00 
Yes 7 35.00 
Thyroglobulin antibodies   
Negative 15 75.00 
Positive 5 25.00 
N, number; %, proportion. 
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Tab. 2 Adverse events 
 Any grade Grade 3-4 
 N % N % 
Weight loss 17 85.00 0 0.00 
Anorexia 16 80.00 0 0.00 
Fatigue 19 95.00 1 5.00 
Hand-foot syndrome 13 65.00 1 5.00 
Rash, desquamation 8 40.00 0 0.00 
Gastrointestinal symptoms 14 70.00 3 15.00 
Alopecia 10 50.00 0 0.00 
Mucositis 11 55.00 0 0.00 
Blood pressure increase  9 45.00 0 0.00 
Abdominal pain 1 5.00 0 0.00 
Syncope 1 5.00 0 0.00 
Acute myocardial infarction 1 5.00 1 5.00 
Intra-tracheal bleeding 1 5.00 1 5.00 
Anaphylactic reaction 1 5.00 0 0.00 
Any adverse event 20 100.00 7  35.00 
N, number; %, proportion. 
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